STOCK TITAN

Protalix Biother Stock Price, News & Analysis

PLX NYSE

Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.

Protalix BioTherapeutics (NYSE: PLX) is a biopharmaceutical innovator leveraging its proprietary ProCellEx® plant cell-based technology to develop enzyme replacement therapies for rare diseases. This page provides investors and industry stakeholders with timely updates on clinical developments, regulatory milestones, and strategic partnerships.

Access comprehensive coverage of PLX's advancements in treating Gaucher disease, Fabry disease, and other rare conditions. Track updates across three key areas: clinical trial progress for pipeline candidates, commercial partnerships with global pharmaceutical leaders, and manufacturing innovations through the ProCellEx® platform.

Our curated news collection enables efficient monitoring of FDA submissions, earnings reports, and licensing agreements. Stay informed about the company's unique approach to cost-effective bioproduction and its expanding role in addressing unmet medical needs through plant-based protein expression systems.

Bookmark this page for direct access to verified press releases and objective analysis of Protalix's position within the competitive rare disease therapeutics market. Regular updates ensure you maintain current awareness of developments impacting both clinical outcomes and investment considerations.

Rhea-AI Summary

Protalix BioTherapeutics, Inc. will announce its financial results for the first quarter of 2024 on May 10, 2024, along with a business and clinical update. The company focuses on developing and commercializing recombinant therapeutic proteins. Investors can join the conference call and webcast to discuss the results and recent developments. The call details are provided for easy access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.87%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.38%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences

FAQ

What is the current stock price of Protalix Biother (PLX)?

The current stock price of Protalix Biother (PLX) is $1.41 as of July 11, 2025.

What is the market cap of Protalix Biother (PLX)?

The market cap of Protalix Biother (PLX) is approximately 122.6M.
Protalix Biother

NYSE:PLX

PLX Rankings

PLX Stock Data

122.59M
71.33M
13.7%
5.98%
6.86%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Israel
HACKENSACK